TTNP Titan Pharmaceuticals Inc.

0.17
-0.01  -4%
Previous Close 0.18
Open 0.18
Price To Book -3.46
Market Cap 9,926,531
Shares 57,378,794
Volume 5,906,391
Short Ratio
Av. Daily Volume 6,583,801
Stock charts supplied by TradingView

NewsSee all news

  1. Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 3, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays

  2. Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

  3. Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business.

  4. Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow

    SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, 2019.  Following the

  5. Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 3, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays

  2. Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

  3. Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business.

  4. Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow

    SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, 2019.  Following the

  5. Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has

  6. Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's